SAN DIEGO Amylin has named a new SVP research and development and SVP and chief medical officer, the drug maker announced Tuesday.
Christian Weyer, a 10-year Amylin veteran, was named SVP research and development after serving as VP medical development. In his new role, Weyer will lead Amylin's R&D organization, focusing on expanding opportunities with the company's existing diabetes products, advancing the obesity and early diabetes pipeline, and driving research programs that support innovation and business growth, the drug maker said.
Weyer replaces Orville Kolterman, who was named SVP and chief medical officer of the company, where he will work to further strengthen Amylin's ties with the medical community, policy-makers, patient advocacy groups and other audiences.
"The changes announced [today] will sharpen Amylin's focus in areas that are critical to our near- and long-term success," said Daniel Bradbury, president and CEO at Amylin. "Chris is a seasoned R&D leader with a strong scientific background in endocrinology and metabolism, as well as solid business and management experience. His proven ability to expand and enable the Amylin pipeline will be invaluable in his new leadership role as we continue progress on promising programs that could transform the lives of patients."